COMPASS Pathways plc

NasdaqGS:CMPS Stock Report

Market Cap: US$453.1m

COMPASS Pathways Valuation

Is CMPS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CMPS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CMPS ($6.63) is trading below our estimate of fair value ($164)

Significantly Below Fair Value: CMPS is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for CMPS?

Other financial metrics that can be useful for relative valuation.

CMPS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-1.8x
PEG Ration/a

Price to Book Ratio vs Peers

How does CMPS's PB Ratio compare to its peers?

The above table shows the PB ratio for CMPS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average2.2x
NGNE Neurogene
2.9x-32.5%US$454.8m
ABSI Absci
2.1x20.1%US$456.5m
SAGE Sage Therapeutics
0.7x39.3%US$457.9m
ALT Altimmune
2.9x20.2%US$440.6m
CMPS COMPASS Pathways
2x39.4%US$453.1m

Price-To-Book vs Peers: CMPS is good value based on its Price-To-Book Ratio (2x) compared to the peer average (2.2x).


Price to Earnings Ratio vs Industry

How does CMPS's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a29.8%
n/an/an/a
No. of CompaniesPB048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a29.8%
n/an/an/a
No more companies

Price-To-Book vs Industry: CMPS is expensive based on its Price-To-Book Ratio (2x) compared to the US Biotechs industry average (1.9x).


Price to Book Ratio vs Fair Ratio

What is CMPS's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CMPS PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CMPS's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CMPS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$6.63
US$38.22
+476.9%
78.9%US$120.00US$22.00n/a9
Sep ’25US$7.48
US$38.22
+411.0%
78.9%US$120.00US$22.00n/a9
Aug ’25US$6.88
US$38.44
+458.8%
78.6%US$120.00US$22.00n/a9
Jul ’25US$5.95
US$40.38
+578.6%
78.1%US$120.00US$22.00n/a8
Jun ’25US$7.38
US$41.25
+458.9%
75.5%US$120.00US$22.00n/a8
May ’25US$8.48
US$43.86
+417.2%
74.0%US$120.00US$22.00n/a7
Apr ’25US$9.68
US$40.38
+317.1%
78.6%US$120.00US$16.00n/a8
Mar ’25US$11.48
US$41.86
+264.6%
80.4%US$120.00US$16.00n/a7
Feb ’25US$11.34
US$43.00
+279.2%
77.2%US$120.00US$16.00n/a7
Jan ’25US$8.75
US$43.00
+391.4%
77.2%US$120.00US$16.00n/a7
Dec ’24US$6.10
US$45.43
+644.7%
69.8%US$120.00US$22.00n/a7
Nov ’24US$5.78
US$44.50
+669.9%
67.7%US$120.00US$21.00n/a8
Oct ’24US$7.40
US$44.50
+501.4%
67.7%US$120.00US$21.00n/a8
Sep ’24US$9.33
US$44.50
+377.0%
67.7%US$120.00US$21.00US$7.488
Aug ’24US$8.95
US$44.89
+401.6%
64.4%US$120.00US$21.00US$6.889
Jul ’24US$8.28
US$42.30
+410.9%
67.4%US$120.00US$19.00US$5.9510
Jun ’24US$7.59
US$42.30
+457.3%
67.4%US$120.00US$19.00US$7.3810
May ’24US$8.08
US$42.30
+423.5%
67.4%US$120.00US$19.00US$8.4810
Apr ’24US$9.93
US$41.55
+318.4%
65.7%US$120.00US$19.00US$9.6811
Mar ’24US$8.13
US$41.55
+411.0%
65.7%US$120.00US$19.00US$11.4811
Feb ’24US$10.61
US$45.91
+332.7%
54.4%US$120.00US$30.00US$11.3411
Jan ’24US$8.03
US$45.91
+471.7%
54.4%US$120.00US$30.00US$8.7511
Dec ’23US$10.22
US$55.09
+439.0%
57.0%US$120.00US$30.00US$6.1011
Nov ’23US$10.65
US$57.60
+440.8%
55.4%US$120.00US$30.00US$5.7810
Oct ’23US$10.73
US$65.11
+506.8%
49.8%US$120.00US$30.00US$7.409
Sep ’23US$16.10
US$65.11
+304.4%
49.8%US$120.00US$30.00US$9.339

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies